SARS2
Serine--tRNA ligase, mitochondrial
Also known as: FLJ20450, mtSerRS, SARS, SARSM, SerRSmt, SERS, SYS, SYSM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9NP81
- Gene
- SARS2
- Ensembl
- ENSG00000104835
- Chromosome
- 19
- Canonical length
- 518 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Vesicles,Mitochondria
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes the mitochondrial seryl-tRNA synthethase precursor, a member of the class II tRNA synthetase family. The mature enzyme catalyzes the ligation of Serine to tRNA(Ser) and participates in the biosynthesis of selenocysteinyl-tRNA(sec) in mitochondria. The enzyme contains an N-terminal tRNA binding domain and a core catalytic domain. It functions in a homodimeric form, which is stabilized by tRNA binding. This gene is regulated by a bidirectional promoter that also controls the expression of mitochondrial ribosomal protein S12. Both genes are within the critical interval for the autosomal dominant deafness locus DFNA4 and might be linked to this disease. Multiple transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]
Canonical amino-acid sequenceUniProt
518 residues, UniProt reviewed canonical sequence.
>Q9NP81|SARS2
1 MAASMARRLW PLLTRRGFRP RGGCISNDSP RRSFTTEKRN RNLLYEYARE GYSALPQLDI
61 ERFCACPEEA AHALELRKGE LRSADLPAII STWQELRQLQ EQIRSLEEEK AAVTEAVRAL
121 LANQDSGEVQ QDPKYQGLRA RGREIRKELV HLYPREAQLE EQFYLQALKL PNQTHPDVPV
181 GDESQARVLH MVGDKPVFSF QPRGHLEIGE KLDIIRQKRL SHVSGHRSYY LRGAGALLQH
241 GLVNFTFNKL LRRGFTPMTV PDLLRGAVFE GCGMTPNANP SQIYNIDPAR FKDLNLAGTA
301 EVGLAGYFMD HTVAFRDLPV RMVCSSTCYR AETNTGQEPR GLYRVHHFTK VEMFGVTGPG
361 LEQSSQLLEE FLSLQMEILT ELGLHFRVLD MPTQELGLPA YRKFDIEAWM PGRGRFGEVT
421 SASNCTDFQS RRLHIMFQTE AGELQFAHTV NATACAVPRL LIALLESNQQ KDGSVLVPPA
481 LQSYLGTDRI TAPTHVPLQY IGPNQPRKPG LPGQPAVSLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 18 nTPM
Expression across tissuesHPA
Tissue
- liver: 18 nTPM
- adrenal gland: 17 nTPM
- skeletal muscle: 17 nTPM
- kidney: 17 nTPM
- pancreas: 16 nTPM
- esophagus: 14 nTPM
Single-cell type
- late spermatids: 7.7 nCPM
- distal convoluted tubule cells: 5.2 nCPM
- proximal tubule cells: 5 nCPM
- renal collecting duct intercalated cells: 5 nCPM
- astrocytes: 4.1 nCPM
- erythrocyte progenitors: 4.1 nCPM
Immune cell
- myeloid DC: 25 nTPM
- memory CD8 T-cell: 15 nTPM
- intermediate monocyte: 14 nTPM
- gdT-cell: 14 nTPM
- NK-cell: 14 nTPM
- non-classical monocyte: 14 nTPM
Brain region
- cerebral cortex: 9.7 nTPM
- white matter: 8.8 nTPM
- pons: 8.6 nTPM
- medulla oblongata: 7.4 nTPM
- basal ganglia: 6.9 nTPM
- cerebellum: 6.9 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SARS2.
Disease | AllUniProt
Conditions SARS2 is implicated in, by any mechanism.
- Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome (HUPRAS) MIM:613845
Disease | GeneticClinVar
5 pathogenic / likely-pathogenic of 412 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Hyperuricemia, pulmonary hypertension, renal failure, alkalosis syndrome
- SARS2-associated condition
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.93
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.25
- DepMap mean gene effect
- -0.62
- DepMap dependency class
- common
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 9% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- seryl-tRNA aminoacylation
- mitochondrial seryl-tRNA aminoacylation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminoacyl-tRNA synthetase, class II (G/ P/ S/T)
- Serine-tRNA ligase, type1
- Aminoacyl-tRNA synthetase, class II
- Class I and II aminoacyl-tRNA synthetase, tRNA-binding arm
- Serine-tRNA ligase catalytic core domain
- Serine-tRNA synthetase, type1, N-terminal domain superfamily
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- tRNA synthetase class II core domain (G, H, P, S and T)
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of SARS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SARS2 as an antibody target. Whether an autoantibody or antibody against SARS2 could matter depends on whether native SARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label SARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...